Pharmacological approaches to disease-modifying therapies in Parkinson’s disease

References

• Parkinson J. An essay on the shaking palsy Sherwood, Nelly and Jones, London, UK (1817).
   Google Scholar
• •First description of PD.
   Google Scholar
• Siemers E. Recent progress in the treatment of Parkinson's disease. Comprehensive Therapy18, 20–24 (1992).
   PubMedGoogle Scholar
• Hingtgen CM, Siemers E. The treatment of Parkinson's disease — current concepts and rationale. Comprehensive Therapy 24, 560–566 (1998).
   PubMedGoogle Scholar
• Rajput ML, Rajput AH. Epidemiology of parkinsonism. In: Parkinson's disease. Diagnosis and clinical management. Factor SA, Weiner WJ (Eds). Demos Medical Publishing, New York, USA, 31–40 (2002).
   Google Scholar
• Bezard E, Imbert C, Gross CE. Experimental models of Parkinson's disease: From static to the dynamic. Rev NeuroscL 9, 71–90 (1998).
   PubMed Web of Science ®Google Scholar
• Zigmond MJ, Stricker EM. Animal models of Parkinsonism using selective neurotoxins: Clinical and basic implications. Internat. Rev NeurobioL 31, 1–79 (1989).
   PubMed Web of Science ®Google Scholar
• Siderowf A, Holloway RG. Economic impact of Parkinson's disease: Implications for interventions. In: Parkinson's disease. Diagnosis and clinical management. Factor SA, Weiner WJ (Eds). Demos Medical Publishing, New York, USA, 639–645 (2002).
   Google Scholar
• Hughes AJ, Daniel SE, Kilford L, Lees AJ. The accuracy of the clinical diagnosis of Parkinson's disease: a clinico-pathological study of 100 cases. J. NeuroL Neurosurg. Psychiatry 55, 181–184 (1992).
   Google Scholar
• Hughes AJ, Ben-Schlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study. Neurology 42, 1142–1146 (1992).
   PubMed Web of Science ®Google Scholar
• Nutt JG. Motor fluctuations and dyskinesia. In: Parkinson's disease. Diagnosis and clinical management. Factor SA, Weiner WJ (Eds). Demos Medical Publishing, New York, USA, 445–453 (2002).
   Google Scholar
• Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled-release carbidopa/levodopa in Parkinson's disease. Eur NeuroL 37, 23–27 (1997)
   Google Scholar
• Hornykiewicz 0, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv. NeuroL 45, 19–34 (1987).
   Google Scholar
• Dunnett SB, Björkland A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399, A32–39 (1999).
   PubMed Web of Science ®Google Scholar
• Rabey JM, Burns RS. Neurochemistry. In: Parkinson's disease. Diagnosis and clinical management. Factor SA, Weiner WJ (Eds). Demos Medical Publishing, New York, USA, 195–209 (2002).
   Google Scholar
• Golbe L. The genetics of Parkinson's disease: a reconsideration. Neurology 40, 7–14 (1990).
   PubMed Web of Science ®Google Scholar
• Scott WK, Stajick JM, Yamaoka LH et al. Genetic complexity and Parkinson's disease. Science 277, 387–388 (1997).
   PubMed Web of Science ®Google Scholar
• Vieregge P. Genetic factors in the etiology of idiopathic Parkinson's disease. J. Neural TransmSect1 8, 1–37 (1994).
   Google Scholar
• Tanner CM, Langston JW. Do environmental toxins cause Parkinson's disease? A critical review. Neurology 40, 17–30 (1990).
   PubMed Web of Science ®Google Scholar
• Semchuck K, Love EJ, Lee RG. Parkinson's disease and exposure to rural environmental factors: A population based case-control study. Can. Neurologcal ScL 18, 279–286 (1991).
   Google Scholar
• Schapira AHV. Parkinson's disease. Br. Med. 1318,311–314(1999).
   Google Scholar
• Jenner P, Dexter DT, Sian I, Schapira AH, Marsden CD. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann. NeuroL 32, 583–587 (1992).
   Google Scholar
• Sian J, Dexter DT, Lees AJ et al. Alterations in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. NeuroL 36, 348–355 (1994).
   PubMed Web of Science ®Google Scholar
• Kish SJ, Morito C, Hornykiewicz 0. Glutathione peroxidase activity in Parkinson's disease brain. NeuroscL Lett. 58, 343–346 (1995).
   Google Scholar
• Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD. Glutathione-related enzymes in brain in Parkinson's disease. Ann. NeuroL 36, 356–361 (1994).
   PubMed Web of Science ®Google Scholar
• Pennarthur S, Jackson-Lewis V, Przedborski S, Heinecke JW Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine and o,o'-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. Biol. Chem. 274, 34621–34628 (1999).
   Google Scholar
• Good PF, Hsu A, Werner P, Per DP, Olanow CW Protein nitration in Parkinson's disease. J. Neuropathol. Exp. NeuroL 57, 338–339 (1998).
   PubMed Web of Science ®Google Scholar
• Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Dis. 13, 24–34 (1998).
   PubMed Web of Science ®Google Scholar
• Tatton NA, Kish SJ. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methy1-4-pheny1-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience77, 1037–1048 (1997).
   PubMed Web of Science ®Google Scholar
• Tatton NA Increased caspase-3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. NeuroL 16, 29–43 (2000).
   Google Scholar
• Hartmann A, Hunot S, Michel PP et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc. Natl Acad. Sci. USA 97, 2875–2880 (2000).
   Google Scholar
• Yang L, Matthews RT, Schulz JB et al. 1- methy1-4-pheny1-12,3,6-tetrahydropyride neurotoxicity is attenuatede in mice overexpressing Bc1-2. j Neurosci. 18, 408–412 (1998).
   Web of Science ®Google Scholar
• •Demonstrated that an antiapoptotic protein could provide protection against MPTP toxicity in mice.
   Google Scholar
• Langston JVV, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methy1-4-pheny1-1,2,3,6-tetrahydropyridine exposure. Ann. NeuroL 46, 598–605 (1999).
   Google Scholar
• Kurkowska-Jastrezebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A. The inflammatory reaction following 1-methy1-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp. Neural 156, 50–61 (1999).
   Google Scholar
• Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the a-synuclein gene identified in families with Parkinson's disease. Science 276, 2045–2047 (1997)
   PubMed Web of Science ®Google Scholar
• Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. a-synuclein in Lewy bodies. Nature 388, 839–840 (1997).
   PubMed Web of Science ®Google Scholar
• Goedert M. Alpha-synuclein and neurodegenerative diseases, Nat. Rev Neurosci. 2, 492–501 (2001).
   Google Scholar
• •Very good review on a-synuclein family and role in PD and Lewy body diseases.
   Google Scholar
• Shimura H, Schlossmacher MG, Hattori N et al. Ubiquitination of a new form of a-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263–269 (2001).
   PubMed Web of Science ®Google Scholar
• Gasser T. Genetics of Parkinson's disease. J. Neurol. 248, 833–840 (2001).
   PubMed Web of Science ®Google Scholar
• Mouradian MM. Recent advances in the genetics and pathogenesis of Parkinson's disease. Neurology 58, 179–185 (2002).
   PubMed Web of Science ®Google Scholar
• Gershanik OS. Juvenile and young-onset parkinsonism. In: Parkinson's disease. Diagnosis and clinical management. Factor SA, Weiner WJ (Eds). Demos Medical Publishing, New York, USA, 577–589 (2002).
   Google Scholar
• Hedrich K, Marder K, Harris J et al. Evaluation of 50 probands with early-onset Parkinson's disease for Parkin mutations. Neurology58, 1239–1246 (2002).
   PubMed Web of Science ®Google Scholar
• McNaught KSP, Olanow CA, Halliwell B, Isacson 0, Jenner P. Failure of the ubiquitin-proteosome system in Parkinson's disease. Nat. Rev Neurosci. 2, 589–594 (2001).
   Google Scholar
• Cotzias GC, Papavasiliou PS, Gellene R. Modifications of parkinsonism — chronic treatment with L-dopa. N Engl. J. Med. 280, 337–345 (1969).
   Google Scholar
• Lieberman AN, Gopinathan G, Neophytides A, Foo SH. Deprenyl versus placebo in Parkinson's disease. A double-blind study. NY State J. Med. 87, 646–649 (1987).
   PubMedGoogle Scholar
• Golbe LI, Lieberman AN, Muenter MD et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin. NeuropharmacoL 11,45–55, 1988.
   PubMed Web of Science ®Google Scholar
• The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl. J. Med. 321, 1364–1471 (1989).
   PubMed Web of Science ®Google Scholar
• Tetrud J, Langston W The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 245, 519–522 (1989).
   PubMed Web of Science ®Google Scholar
• Factor SA. Dopamine agonists. Med. Clin. N Am. 83, 415–443 (1999).
   PubMed Web of Science ®Google Scholar
• Montastruc JL, Rascol 0, Senard JM. Current status of dopamine agonists in Parkinson's disease management. Drugs. 46(3), 384–393 (1993).
   Google Scholar
• Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology56\(Suppl. 5), S1—S88 (2001).
   Google Scholar
• Pezzoli G, Martignoni E, Pacchetti C et al. Pergolide compared with bromocriptine in Parkinson's disase: a multicenter, cross-over, conrolled study. Mov. Disord 9,431–436 (1994).
   PubMed Web of Science ®Google Scholar
• Boas J, Worm-Petersen J, DuPont E, Mikkelsen B, Wermuth L. The levodopa dose-sparing capacity of pergolide compared with that of bromocriptine in an open-label, cross-over study. Eur. j NeuroL 3, 44–49 (1996).
   Web of Science ®Google Scholar
• Goetz CG, Diederich NJ. Dopaminergic agonists in the treatment of Parkinson's disease. Neurologic Clinics10 (2), 527–540 (1992).
   PubMed Web of Science ®Google Scholar
• Tulloch IF. Pharmacologic profile of ropinirole: A nonergoline dopamine agonist. Neurology49\(Suppl. 1), S58—S62 (1997).
   Google Scholar
• Shannon KM, Bennett JP, Friedman JH for the Pramipexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 49, 724–728 (1997).
   Google Scholar
• Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson's disease: A randomized controlled trial. JAMA 284, 1931–1938 (2000).
   PubMed Web of Science ®Google Scholar
• Rascol 0, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, for the 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson' disease who were treated with ropinirole or levodopa. N Engl. Med. 342, 1484–1491 (2000).
   Google Scholar
• Hundemer HP, Lledo A, van Laar T et al. The safety of pergolide monotherapy in early-stage Parkinson's disease. One-year interim analysis of a 3-year double-blind, randomized study of pergolide versus levodopa. Mov. Disord 15 (Suppl. 3), 115 (2000).
   Google Scholar
• Rinne UK, Bracco F, Chouza C et al. Early treatment of Parkinson's disease wih cabergoline delays the onset of motor complications: results of a double-blind levedopa controlled trial. Drugs 55 (Suppl. 1), 23–30 (1998).
   Google Scholar
• Colosimo C. The rise and fall of tolcapone. NeuroL 246, 880–882 (1999).
   Web of Science ®Google Scholar
• Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double-blind study in parkinsonian patients with levodopa related fluctuations. NeuroL Neurosurg. Psychiatry 60, 36–40 (1996).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann. NeuroL 42, 747–755 (1997).
   PubMed Web of Science ®Google Scholar
• Factor SA, Weiner WJ. Parkinson's disease. Diagnosis and clinical management. Demos Medical Publishing, New York, USA (2002).
   Google Scholar
• Marsden CD. Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet. 1, 345–349 (1977).
   PubMed Web of Science ®Google Scholar
• Marder K, Jacobs DM. Dementia. In: Parkinson's disease. Diagnosis and clinical management. Factor SA, Weiner WJ (Eds). Demos Medical Publishing, New York, USA, 125–135 (2002).
   Google Scholar
• Marsden CD, Linazasoro G, Obeso JA. An introduction to the new surgery for Parkinson's disease. Past and present problems. Advances in Neurology 74, 143–147 (1997).
   Google Scholar
• Olanow CW, Freeman TB, Kordower JH. Neural transplantation as a therapy for Parkinson's disease. Advances in Neurology 74, 249–269 (1997).
   Google Scholar
• Freed CR, Greene PE, Breeze RE eta]. Transplantation of embryonic dopaminergic neurons for severe Parkinson's disease. N Engl. j Med. 344, 710–719 (2001).
   Google Scholar
• •First double-blind, placebo-controlled trial of embryonic tissue transplantation in PD.
   Google Scholar
• Brooks DJ. Positron emission tomography studies in movement disorders. Neurosurg. Clin. N Am. 9(2), 263–282 (1998).
   Google Scholar
• Carlsson A, Lundqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Natum 180, 1200 (1957).
   Google Scholar
• Schallert T, Teitelbaum P. Haloperidol, catalepsy and equilibrating functions in the rat: an antagonist interaction of clinging and labyrinthine righting reactions. PhysioL Behav. 27, 1077–1083 (1981).
   PubMed Web of Science ®Google Scholar
• Porter CC, Totara J, Stone C.A. Effect of 6- hydroxydopamine and some other compounds on the concentration of noradrenaline in the hearts of mice. PharmacoL Exp. Ther. 140, 308–316 (1963).
   Google Scholar
• Ungerstedt U. 6-hydroxydopamine-induced degeneration of central monoamine neurones. Eur. j PharmacoL 5, 107–110 (1968).
   Google Scholar
• Heikkila RE, Cohen G. Further studies on generation of hydrogen peroxide by 6-hydroxydopamine: potentiation by ascorbic acid. MoL Pharmacol. 8, 241–248 (1972).
   PubMed Web of Science ®Google Scholar
• Sachs CH, Jonsson G. Mechanism of action of 6-hydroxydopamine. Pharmacology 24, 1–8 (1975).
   Google Scholar
• Davis GC, Williams AC, Markey SP et al. Conic Parkinsonism secondary to iv. injection of meperidine analogues. Psychiat. Res. 1, 249–254 (1979).
   PubMed Web of Science ®Google Scholar
• •First report that a by-product of the chemical synthesis of a meperidine analog (MPTP) could produce parkinsonism in humans.
   Google Scholar
• Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to MPTP: 7 cases. Neurology 35, 969–976 (1985).
   Google Scholar
• Langston JW, Ballard P, Tetrud JW et al. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979 (1983).
   PubMed Web of Science ®Google Scholar
• Przedborski S, Jackson-Lewis V, Naini AB et al. The parkinsonian toxin 1-methly-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. Neurochem. 76, 1265–1274 (2001).
   PubMed Web of Science ®Google Scholar
• •Very good review on the use of MPTP (storage, injection, metabolism, protective equipment, cages, rooms etc.) in animal models of PD.
   Google Scholar
• Flint Beal M. Experimental models of Parkisnon's disease. Nat. Rev Neurosci. 2, 326–332 (2001).
   Web of Science ®Google Scholar
• Betarbet R, Sherer TB, Mackenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 12, 1301–1306 (2000).
   Google Scholar
• •Reported that slow systemic infusion of rotenone produced a slow progressive loss in dopaminergic neurons and had associated inclusion bodies.
   Google Scholar
• Abeliovich A, Schmitz Y, Farifias I et al. Mice lacking a-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239–252 (2000).
   PubMed Web of Science ®Google Scholar
• Masliah E, Rockenstein E, Veinbergs L et al. Dopaminergic loss and inclusion body formation in a-synuclein mice: Implications for neurodegenerative disorders. Science 287, 1265–1269 (2000).
   PubMed Web of Science ®Google Scholar
• •First reported evidence that overexpression of a-synuclein could produce inclusion bodies, dopaminergic loss and behavioral abnormalities in mice
   Google Scholar
• Masliah E, Rockenstein E, Veinbergs I et al. 13-amyloid peptides enhance a-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc. Natl Acad. Sci. USA 21, 12245–12250 (2001).
   Google Scholar
• Feany MB, Bender WW. Drosophila model of Parkinson's disease. Nature 404, 394–398 (2000).
   PubMed Web of Science ®Google Scholar
• •Interesting model where in flies (Drosophila) showing that overexpression of both wild type and mutant a-synuclein resulted in loss of dopamine neurons and produced inclusion bodies.
   Google Scholar
• Bradford HF, Zhou J, Pliego-Rivero B, Stern GM, Jauniaux E. Neurotrophins in the pathogenesis and potential treatment of Parkinson's disease. Parkinson's disease: Advances in Neurology80, 19–25 (1999).
   Google Scholar
• Yurek D, Fletcher-Turner A. Differential expression of GDNF, BDNF and NT-3 in the aging nigrostriatal system following a neurotoxic lesion. Brain Res. 891, 228–235 (2001).
   PubMed Web of Science ®Google Scholar
• Howells DW, Porritt MJ, Wong JY et al. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp. NeuroL 166, 127–135 (2000).
   PubMed Web of Science ®Google Scholar
• Mogi M, Togari A, Kondo T et al. Brain- derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neuroscience Letters 270, 45–48 (1999).
   PubMed Web of Science ®Google Scholar
• Altar CA, Boylan CB, Fritsche M et al. Efficacy of brain-derived neurotropic factor and neurotrohin-3 on neurochemical and behavioral deficits associated with partial nigrostrial dopamine lesions. j Neurochem. 63, 1021–1032 (1994).
   PubMed Web of Science ®Google Scholar
• Altar CA, Boylan CB, Jackson C et al. Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc. Natl Acad. Sci. USA 89,11347–11351 (1992).
   PubMed Web of Science ®Google Scholar
• Rosenbald C, Kink D, Bjorklund A. Sequential administrtaion of GDNF into the substantia nigra and straitum promotes dopamine neurone survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-0HDA lesion model, Exp. Neurol. 161,503-516 (2000).
   Google Scholar
• O'Neill MJ, Carney SL. Role of BDNF in psychiatric and Neurological Disorders. Curr. Topics Neurochem. an Press).
   Google Scholar
• Klein RL, Lewis MH, Muzyczka N, Meyer EM. Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer, Brain Res. 847,314–320 (1999).
   Google Scholar
• Nakajima K, Hida H, Shimano Y et a/. GDNF is a major component of trophic activity in DA-depleted striatum for survival and neurite extension of DAergic neurons. Brain Res. 916,76–84 (2001).
   Google Scholar
• Tomac A, Lindqvist E, Lin LFH et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373,335–339 (1995).
   PubMed Web of Science ®Google Scholar
• •First report that GDNF had restorative effects on dopaminergic neurons after MPTP treatment.
   Google Scholar
• Gash DM, Zhang Z, Ovadia A et al. Functional recovery in parkinsonian monkeys treated with GDNE Nature 380, 252–255 (1996).
   Google Scholar
• Fox CM, Gash DM, Smoot MK, Cass WA. Neuroprotective effects of GDNF against 6-0HDA in young and aged rats. Brain Res. 896,56–63 (2001).
   PubMed Web of Science ®Google Scholar
• Kordowder JH, Emborg ME, Bloch J et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767–773 (2000).
   PubMed Web of Science ®Google Scholar
• •Very nice study demonstrating a very effective prevention of MPTP-induced dopamine loss using lentiviral delivery of GDNF.
   Google Scholar
• Nutt JG, Bronstein JM, Carter JH et al. Intraventricular administration of GDNF in the treatment of Parkinson's disease. Neurology56\(Suppl. 3), A375 (2001).
   Google Scholar
• Schulz JB, Matthews RT, Muqit MMK, Browne SE, Flint Beal ME Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP- induced neurotoxicity in mice. J.Neurochem. 64,936-939 (1995).
   Google Scholar
• •First paper showing that an nNOS inhibitor could attenuate MPTP-induced neurotoxicity in vivo.
   Google Scholar
• Hantraye P, Brouillet E, Ferrante R et al. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat. Med. 2,1017–1021 (1996).
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer EG, Kawamata T et al. Reactions of the immune system in chronic degenerative neurological diseases. Can. J. Neurol. Sci. 18 (Suppl. 3), 376–379 (1991).
   Google Scholar
• McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's diease brains. Neurology38, 1285–1291 (1988).
   PubMed Web of Science ®Google Scholar
• Shults CW, Haas RH, Passov D, Beal ME Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann. Neurol. 42, 261–264 (1997).
   Google Scholar
• Shults CW, Haas RH, Beal ME A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. Biofactors 9,267–272 (1999).
   PubMed Web of Science ®Google Scholar
• Beal ME Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. Biofactors 9, 261–266 (1999).
   PubMed Web of Science ®Google Scholar
• Cohen G, Spina MB. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann. Neurol. 26,689–690 (1989).
   PubMed Web of Science ®Google Scholar
• Foley P, Gerlach M, Youdim MBH et al. MAO-B inhibitor: multiple roles in the therapy of neurodegenerative disorders? Parkinsonism Relat. Disord 6,25–47 (2000).
   Google Scholar
• Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl. J. Med. 328, 176–183 (1993). Hi Movement Disorder Society Task Force for Evidence Based Medicine. MAO-B inhibitors for the treatment of Parkinson's disease. Mov. Disord 17\(Suppl. 4), S38—S44 (2002).
   Google Scholar
• Schapira AHV Neuroprotection and dopamine agonists. Neurology58(4 Suppl. 1),S9—S18 (2002).
   Google Scholar
• Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson's disease progression. JAMA 287, 1653–1661 (2002).
   Google Scholar
• Whone AL, Remy P, Davis M et al. The REAL-PET study: slower porgression in early Parkinson's disease treated with ropinirole compared with L-dopa. Neurology58, S11.006 (2002).
   Web of Science ®Google Scholar
• Ishikawa A, Miyatake T. Effects of smoking in patients with early-onset Parkinson's disease. J. Neurol. Sci. 117, 28–32 (1993).
   PubMed Web of Science ®Google Scholar
• Fagerstrom KO, Pomerleau 0, Giordani B, Stelson E Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology 116,117–119 (1994).
   PubMed Web of Science ®Google Scholar
• Imperato A, Mulas A, di Chiara G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur j Pharmacol. 132, 337–338 (1986).
   Google Scholar
• Rapier C, Lunt GG, Wonacott S. Stereoselective nicotine-induced release of dopamine from striatal synaptosomes: concentration dependence and repetitive stimulation. J. Neurochem. 50,1123-1130 (1988).
   Google Scholar
• Schneider JS, Pope-Colman A, Van Velson M, Menzaghi F, Lloyd GK. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys. Mov. Disord 4, 637–642 (1998).
   Google Scholar
• Baron JA. Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious. Br. Med. Bull. 52,58–73 (1996).
   PubMed Web of Science ®Google Scholar
• Balfour DJK, Fagerstrom KO. Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. Pharmacol. Therapeutics 72,51–81 (1996).
   PubMed Web of Science ®Google Scholar
• O'Neill MJ, Murray TK, Lakics V, Visanji NP, Duty S. The role of neuronal nicotinic receptors in acute and chronic neurodegeneration. Current Drug Targets - CNS & Neurological Disordersl (4), 399–412 (2002).
   Google Scholar
• Maggio R, Riva M, Vaglini F et al. Nicotine prevents experimental Parkinsonism in rodents and induces striatal increase of neurotrophic factors. J. Neurochem. 71, 2439–2446 (1998).
   PubMed Web of Science ®Google Scholar
• Blindauer K and Parkinson Study Group. Double-blind, placebo-controlled, dose-ranging study of the safety and tolerability of SIB-1508Y, a nicotinic receptor agonist, in early Parkinson's disease patients. Neurology54\(Suppl. 3), A278 (2000).
   Google Scholar
• Steiner JP, Hamilton GS, Ross DT et al. Suzdak Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc. Natl Acad. Sci. USA 94, 2019–2024 (1997).
   PubMed Web of Science ®Google Scholar
• •First report that immunophilins could produce trophic effects against MPTP-induced neurotoxicity in vivo.
   Google Scholar
• Seibyl JP, Marek K, Jennings D, Powe L, Nil-A Trial Group. 1231 0-GT SPECT imaging assessment of Parkinson's disease patients treated for six months with a neuroimmunophilin ligand. Neurology 58 P03.066 (2002).
   Google Scholar
• Klivenyi P, Ferrante RJ, Matthews RT et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 5, 347–350 (1999).
   PubMed Web of Science ®Google Scholar
• Vila M, Jackson-Lewis V, Vukosavic S et al. Box ablation prevents dopaminergic neurodegeneration in the 1-methy1-4-pheny1-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad. Sci. USA 98, 2837–2842 (2001).
   Google Scholar
• Trimmer PA, Smith TS, Jung AB, Bennett JP Jr. Dopamine neurons from transgenic mice with a knockout of p53 gene resist MPTP neurotoxicity. Neurodegeneration 5, 233–239 (1996).
   Google Scholar
• Eberhardt 0, Coelln RV, Kugler S et al. Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methy1-4-pheny1-1,2,3,6-tetrahydropyridine model of Parkinson's disease. j Neurosci. 20, 9126–9134 (2000).
   Google Scholar
• Saporito MS, Brown EM, Miller MS, Carswell S. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methy1-4-phenyl-tetrahydropyridine-mediated loss of nigrostriatal neurons in vivo. j Pharmacol. Exp. Ther. 288, 421–427 (1999).
   Google Scholar
• Saporito MS, Thomas BA, Scott RW. MPTP activates c-jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MIKK4 in nigrostriatal neurons in vivo. j Neurochem. 75, 1200–1208 (2000).
   Google Scholar
• Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann. Neurology19, 105–111(1986).
   PubMed Web of Science ®Google Scholar
• O'Neill MJ, Lees KR. Effects of Ionotropic Glutamate antagonists in Stroke. In: Ionotropic Glutamate Receptors as Therapeutic Targets. Danysz W, Lodge D, Parsons CG (Eds), FP Graham Publishing Co., TN, USA, 403-447(2002).
   Google Scholar
• Mitchell U, Clarke CE, Boyce S et al. Neural mechanisms underlying parkinsonian symptoms based on regional uptake of 2-deoxyglucose in monkeys exposed to 1-methy1-4-pheny1-1,2,3,6,-tetrahydropyridine (MPTP). Neuroscience 32, 213–226 (1989).
   PubMed Web of Science ®Google Scholar
• Bergman H, Wichmann T, Delong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249, 1346–1348 (1990).
   Google Scholar
• Starr MS, Starr BS, Kaur S. Stimulation of basal and L-DOPA-induced motor activity by glutamate antagonists in animal models of Parkinson's disease. Neurosci. Biobehav. Rev 21, 437–446 (1997).
   Google Scholar
• Hunter C, Jankovic J. Double-blind, placebo-controlled study to assess safery and efficacy of riluzole as a neuroprotective drug in patients with early, untreated Parkinson's disease. Neurology52\(Suppl. 2), 214–215 (1999).
   Google Scholar
• Merims D, Ziv I, Djaldetti R et al. Riluzole for levadopa-induced dyskinesias in advanced Parkinson's disease. Lancet 353, 1764–1765 (1999).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD. Neurology 54, 1583–1588 (2000).
   PubMed Web of Science ®Google Scholar
• Shoulson I, Penney J, McDermott M et al. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology 56(4), 455–462 (2001).
   PubMed Web of Science ®Google Scholar
• Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57, 397–404 (2001).
   PubMed Web of Science ®Google Scholar
• Adler CH. Amantadine and anticholinergics. In: Parkinson's disease. Diagnosis and clinical management. Factor SA, Weiner WJ (Eds). Demos Medical Publishing, New York, USA, 357–364 (2002).
   Google Scholar
• Movement Disorder Society Task Force for Evidence Based Medicine. Amantadine/ antiglutamate for the treatment of Parkinson's disease. Mov. Disord. 17\(Suppl. 4), 513—S22 (2002).
   Google Scholar
• Bradley SR, Marino MJ, Wittmann M et al. Activation of Group II metabotropic receptors inhibits synaptic excitation of the substantia nigra pars reticulata. j Neurosci. 20, 3085–3094 (2000).
   PubMed Web of Science ®Google Scholar
• Dawson L, Chadha A, Megalou M, Duty S. The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat. Br. .1. Pharmacol. 129, 541–546 (2000).
   Google Scholar
• Konieczny J, Osowska K, Wolfarth S, Pilc A. LY354740, a Group II metabotropic receptor agonist with potential antoparkinsonian properties in rats. Naunyn-Schmiedebergs Archives of Pharmacology 358, 500–502 (1998).
   PubMed Web of Science ®Google Scholar
• Nicoletti F, Bruno V, Copani A, Casabona G, Knopfel T. Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci. 19, 267–271 (1996).
   Google Scholar
• Kingston AE, O'Neill MJ, Lam AGM, Bales KR, Monn, JA, Schoepp DD. Neuroprotection by metabotropic receptor agonists: LY354740, LY379268 and LY389795. Eur. Pharmacol. 377, 155–165 (1999).
   Google Scholar
• Bond A, Jones NM, Hicks CA et al. Neuroprotective effects of LY-379268*, a selective Group II metabotropic glutamate receptor agonist: investigation into possible mechanism of action. .1. Pharmacol. Exp. Ther. 284, 800–809 (2000).
   Google Scholar
• Bruno V, Battaglia G, Casabona G, Copani A, Caciagli F, Nicoletti E Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-P. Neurosci. 18, 9594–9600 (1998).
   PubMed Web of Science ®Google Scholar
• Matarredona ER, Santiago M, Venero JL, Cano J, Machado A. Group II metabotropic gluatmate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotropic factor induction. .1. Neurochem. 76, 351–360 (2001).
   Google Scholar
• Murray TK, Messenger MJ, Ward MA et al. Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol Biochem. Behav 73, 455–467 (2002)
   Google Scholar
• Kanada T, Jackson MJ, Smith LA et al. Adenosine A2A antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol 43,507–513 (1998).
   Google Scholar
• Ikeda K, Kurokawa M, Aoyama S, Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. j Neurochem. 80, 262–270 (2002).
   PubMed Web of Science ®Google Scholar
• Dunnett SB, Björkland A, Lindvall 0. Cell therapy in Parkinson's disease — stop or go? Nat. Rev. Neurosci. 2,365-369 (2001).
   Google Scholar
• •Good review on the history and clinical issues with using grafts of embryonic tissue to treat PD.
   Google Scholar
• Chichung Lie D, Dziewczapolski G, Willhoite AR, Kaspar BK, Shults CW, Gage FH. The adult subatantia nigra contains progenitor cells with neurogenic potential. j Neurosci. 22,6639–6649 (2002).
   PubMed Web of Science ®Google Scholar
• Kim J-H, Auerbac JM, Rodriguez-Gomez JA et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 418, 50–56 (2002).
   PubMed Web of Science ®Google Scholar
• Chun HS, Son JJ, Son JH. Identification of potential compounds promoting BDNF production in nigral dopaminergic neurons: clinical implication in Parkinson's disease. NeuroReport 3,511–514 (2000).
   Google Scholar
• Quik M, Polonskaya Y, McIntosh JM, Kulak JM. Differential nicotinic receptor expression in monkey basal ganglia: Effects of nigrostrial damage. Neuroscience 112, 619–630 (2002).
   PubMed Web of Science ®Google Scholar
• Hayashi T, Umemori H, Mishina M, Yamamoto T. The AMPA receptor interacts with and signals through the protein tyrosine kinase Lyn. Nature 397,72–76 (1999).
   PubMed Web of Science ®Google Scholar
• Lauterborn JC, Lynch G, Vanderklish P, Arai A, Gall CM. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. j Neurosci. 20,8–21 (2000).
   Google Scholar
• Mackowiak M, O'Neill MJ, Hicks CA, Bleakman D, Skolnick P An AMPA receptor potentiator modulates the expression of BDNF: an in vivo study. Neuropharmacology 43, 1–10 (2002). Affiliations
   Google Scholar